<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>96(9)</volume><submitter>Klickovic U</submitter><funding>Target ALS</funding><funding>Medical Research Council</funding><funding>Brain Research Trust</funding><funding>Motor Neurone Disease Association</funding><funding>UCLH NIHR Biomedical Research Centre</funding><pubmed_abstract>&lt;h4>Background and objectives&lt;/h4>Quantitative and operator-independent biomarkers of disease progression are urgently needed in amyotrophic lateral sclerosis (ALS) research. We assess the potential of skeletal muscle MRI as a sensitive and reliable outcome measure for future ALS clinical trials.&lt;h4>Methods&lt;/h4>In this longitudinal cohort study, muscle MRI of head-neck, upper and lower limb regions, alongside clinical and functional assessments, were acquired at three time points over the individual maximum observation period (iMOP) of 1 year in 20 patients with ALS and 16 healthy controls. Quantitative MRI parameters cross-sectional area (CSA), volume (VOL), fat fraction, functional rest muscle area and water T2 (T&lt;sub>2m&lt;/sub>) were correlated with changes in clinical disease severity (f</pubmed_abstract><journal>Journal of neurology, neurosurgery, and psychiatry</journal><pagination>908-911</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12418527</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Muscle MRI quantifies disease progression in amyotrophic lateral sclerosis.</pubmed_title><pmcid>PMC12418527</pmcid><pubmed_authors>Morrow JM</pubmed_authors><pubmed_authors>Zafeiropoulos N</pubmed_authors><pubmed_authors>Dudziec M</pubmed_authors><pubmed_authors>Sharma N</pubmed_authors><pubmed_authors>Malaspina A</pubmed_authors><pubmed_authors>Zampedri L</pubmed_authors><pubmed_authors>Ziff OJ</pubmed_authors><pubmed_authors>Trimmel K</pubmed_authors><pubmed_authors>Sidle KC</pubmed_authors><pubmed_authors>Shah S</pubmed_authors><pubmed_authors>Fratta P</pubmed_authors><pubmed_authors>Thornton JS</pubmed_authors><pubmed_authors>Greensmith L</pubmed_authors><pubmed_authors>Klickovic U</pubmed_authors><pubmed_authors>Wastling S</pubmed_authors><pubmed_authors>Yousry TA</pubmed_authors><pubmed_authors>Allen J</pubmed_authors><pubmed_authors>Nasel C</pubmed_authors><pubmed_authors>Sinclair CD</pubmed_authors><pubmed_authors>Howard RS</pubmed_authors></additional><is_claimable>false</is_claimable><name>Muscle MRI quantifies disease progression in amyotrophic lateral sclerosis.</name><description>&lt;h4>Background and objectives&lt;/h4>Quantitative and operator-independent biomarkers of disease progression are urgently needed in amyotrophic lateral sclerosis (ALS) research. We assess the potential of skeletal muscle MRI as a sensitive and reliable outcome measure for future ALS clinical trials.&lt;h4>Methods&lt;/h4>In this longitudinal cohort study, muscle MRI of head-neck, upper and lower limb regions, alongside clinical and functional assessments, were acquired at three time points over the individual maximum observation period (iMOP) of 1 year in 20 patients with ALS and 16 healthy controls. Quantitative MRI parameters cross-sectional area (CSA), volume (VOL), fat fraction, functional rest muscle area and water T2 (T&lt;sub>2m&lt;/sub>) were correlated with changes in clinical disease severity (f</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Aug</publication><modification>2026-06-02T00:20:44.677Z</modification><creation>2026-05-24T03:07:40.786Z</creation></dates><accession>S-EPMC12418527</accession><cross_references><pubmed>40132878</pubmed><doi>10.1136/jnnp-2024-335571</doi></cross_references></HashMap>